Abstract
Objective To investigate the effects of metformin on the serum nesfatin 1 and liver steatosis in type 2 dia-betic patients with nonalcoholic fatty liver disease .Methods Selected 60 cases of type 2 DM patients with NAFLD , they were randomly divided into observation group and control group with each group of 30 cases.The control group received diet and ex-ercise therapy;observation group therapy based on diet and exercise plus metformin treatment for 12 weeks.Before and 12 weeks after treatment, compared of the two groups'body mass index (BMI), fasting plasma glucose (FPG), fasting plasma insulin (FIN), glycated serum protein (HbA1c), TC, TG, LDL-C, HDL-C, insulin resistance index(HOMA-IR),nesfatin-1 and other indicators of change .Before treatment and 12 weeks after treatment , all patients received liver CT examination , evaluate the degree of hepatic steatosis .Results Compared with before treatment , after 12 weeks of treatment , BMI, FPG, HOMA-IR, HbA1c , TG, TC, nesfatin-1 in the observation group were significantly improved , and the difference was statisti-cally significant ( P <0.05);the control group BMI, FPG, HOMA-IR, HbA1c, TG, TC decreased slightly,FIN,nesfatin-1, HDL-C, LDL-C showed no significant improvement , there was no statistical difference significance ( P >0.05).Compared with the control group , the observation group BMI , FPG, HOMA-IR, HbA1c , TG, TC, nesfatin-1 have improved significant-ly, and the difference was statistically significant ( P <0.05).After 12 weeks of treatment, total effective rate was 71.43%, higher than the 35.71%in control group( P <0.05).Hepatic steatosis's extent and BMI,HOMA-IR,TG,TC was positively correlated( r =0.396,0.369,0.347,0.428, P <0.05),and nesfatin-1 was negatively correlated ( r =-7.37, P <0.05). Conclusion Metformin can improve insulin resistance , regulate glucose and lipid metabolism , reduce the degree of hepatic steatosis.The nesfatin-1 can regulate the secretion of insulin and glycogen synthesis , probably Metformin, one of the sites of action to improve hepatic insulin resistance , is expected to become a new target for the treatment of type 2 DM merger of NAFLD.关键词
二甲双胍/糖尿病/脂肪肝病,非酒精性/nesfatin-1/肝脂肪变Key words
Metformin/Diabetes/Fatty liver disease,non-alcoholic/Nesfatin-1/Fatty liver disease
